A DIFFERENT APPROACH – “DIRECTLY REVERSING MEMORY DEFICITS”
Since 1991, the Alzheimer’s research community has, according to a 2017 Timmerman Report, “put all its eggs in one basket,” i.e., getting rid of or “clearing” amyloid plaque from the brain.
We think it’s long past time to broaden our thinking.
EIP Pharma is betting on a different mechanism that is based on recent understanding of how stress to the neuron, including that due to amyloid plaques or inflammation, leads to memory deficits. The oral therapy we are developing, neflamapimod inhibits the enzyme p38 MAP Kinase alpha. Activation of p38 alpha kinase in the brain contributes to both increased inflammation and soluble aggregated amyloid-beta, which lead to tau pathology and synaptic dysfunction that result in memory deficits and over time to neurodegeneration.
EIP Pharma licensed neflamapimod in 2014. Prior to licensing neflamapimod, the therapy had previously completed a full chronic toxicology program and demonstrated significant clinical and anti-inflammatory activity in a phase 2a 12-week treatment study in rheumatoid arthritis (RA). After conducting studies that demonstrated the ability of neflamapimod to reverse synaptic dysfunction in animal models, the prior development experience allowed EIP Pharma to go directly to phase 2a clinical trials in patients with Alzheimer's disease . EIP Pharma owns four issued US patents on the administration of neflamapimod to treat Alzheimer’s disease and other CNS disorders and has filed for additional patents in the US and internationally.